Our perspective article on cognitive outcome measures for #AlzheimersDisease clinical trials is out! doi.org/10.1002/alz.12… We aimed to provide a framework to advance the design and implementation of (more) suitable measures to assess clinical efficacy in early AD trials.(1/4)👇
Based on lessons learned from previous AD trials, and leveraging the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology, we provide recommendations to evaluate performance-based cognitive tests for AD clinical trials (Table 2).(2/4)
This framework can be applied when selecting cognitive items/tests for a clinical outcome assessment to evaluate putative treatments, after taking into account factors such as the hypothesized mode of action and target population (e.g. clinical stage) (Table 2/Figure 1).(3/4)
Together, this will hopefully contribute to the much-needed consensus and use of more suitable outcome measures to assess clinical efficacy in early AD trials.(4/4) #ENDALZ @SietskeSikkes @PhilipAlz @johncpc @PappKate @neuroplebeian @AlzheimerAms @alzdemjournals @DrJeffCummings
• • •
Missing some Tweet in this thread? You can try to
force a refresh
